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Abstract: Ethics in biomedical research cannot be defined by etymology, and need a semantic 
definition based on national and contemporary values. In a Nordic cultural and historic context, 
key values are solidarity with one’s fellow man, equality, truth, justice, responsibility, freedom, 
and professionalism. In contemporary medical research, such ethics are further subgrouped 
into research ethics, researcher ethics, societal ethics, and distributive ethics. Lately, public and 
  academic debates have addressed the necessary strengthening of the ethical concerns and interests 
of patients and society. Despite considerable progress, common ethical definitions and control 
systems still lack uniformity or indeed do not exist. Among the cooperative partners involved, 
the pharmaceutical industry have preserved an important role. The same is true for the overall 
judgments reflected by the European Forum for Good Clinical Practice, leading peer-reviewed 
journals, the Nuffield Council on Bioethics for developing nations, and the latest global initiative, 
the Singapore Statement on Research Integrity. To help both institutions and countries, it will be 
valuable to include the following information in academia–industry protocols before starting a 
project: international authorship names; fixed agendas and time schedules for project meetings; 
chairperson shifts, meeting reports, and project plan changes; future author memberships; equal 
blinding and data distribution from disciplinary groups; an equal plan for exchange of project 
manuscripts at the proofing stage; contractual descriptions of all procedures, disagreements, 
publishing rights, prevention, and controls for suspected dishonesty; and a detailed description 
of who is doing what in the working process.
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Introduction
The term “ethics” has obtained linguistic citizenship, especially in relation to biomedical 
research, including clinical and institutional scientific projects. In view of the   common 
misunderstandings, ethics cannot be meaningfully defined by etymology (derived from 
the Greek for “good life”), and needs instead a semantic definition, such as:1
Ethics is an overall term for the immaterial values and attitudes, which are prevalent 
in a country or culture, which lie behind the country’s or culture’s concept of man, the 
derived laws and codes, and which on this basis determines citizens’ personal lives, their 
lives with each other, and with the legal and private institutions of the society.
From a global perspective, ethics also include a responsibility for the ecologic 
balance between the planet Earth, its soil, water, and air, and the diversity of its flora 
and fauna. In the Nordic cultural and historic context, the most important nonmaterial 
values underlying ethics include solidarity with one’s fellow man, equality, truth,   justice, 
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responsibility, freedom, and professionalism.1 However, even 
using existing contemporary semantic definitions of ethics 
(which are few), there are substantial variations between 
cultures, national politics, and languages that are substan-
tial, leading to highly variable interpretation by international 
readers and multicenter project participants. The increasing 
globalization of research now requires definitions that are 
understandable and transparent, in both the geographical 
  universe and the multidisciplinary social universe, eg, 
between epidemiological researchers and the pharmaceutical 
and biomedical industries.
Research, researcher,  
and distributional ethics
Since the mid 20th century, the controlled clinical trial has 
moved from being conducted in existing patients in the 
departments of the researchers to being based often on ran-
domized cohorts from large and fully representative samples, 
based on pretrial epidemiological work. Development of the 
controlled clinical trial and its original ethical perspectives 
after the Second World War has, during the decades since, 
needed to supplement the original ethical demands in human 
biomedical research with several new ethical demands.2 
These include: firstly, researcher ethics, ie, the integrity of 
the individual scientist in carrying out the project and pre-
senting its results, to prevent fraud and dishonesty; secondly, 
societal ethics, ie, dealing with patients as the ultimate target 
group in a globalized perspective, not the drug industry or 
the ambitious scientist; thirdly, distributional ethics, ie, the 
democratic distribution of clinical research results to the 
patient groups in need of them.
From the European perspective alone common definitions 
and control systems either lack uniformity or do not exist. 
Based on a few existing national initiatives, eg, the Nordic 
countries, United States Good Clinical Practice, and   European 
Union initiative, the European Forum for Good Clinical Prac-
tice annual conference at Prague in 2009   concluded that com-
mon European definitions and   coordinated control systems 
are very much needed.   Fortunately, this work has already 
started in the form of a European Union working group.
International reflections
Biomedical and scientific journals are coming to reflect the 
strong public interest in, and demand for, an influential debate 
leading to progress in the ethics of biomedical research, 
thereby strengthening the interests of patients and society. 
The spectrum of participating parties is wide, comprising 
control agencies, professional medical associations, the drug 
industry, clinical and epidemiological researchers, and health 
care researchers from developing countries.
Garattini and Chalmers3 in particular have addressed the 
interests of patients and the public in relation to evaluation 
of drugs in controlled clinical trials. They state that “the drug 
industry has an image problem, and big changes are needed 
to restore public confidence”. Their reasons for this state-
ment are that “… industry research agendas are distorted by 
priorities that are important to industry but not to patients”.4 
Garattini and Chalmers have considered the economic aspects 
of new drugs from the cambrium of basic research, the costs 
of which are met mainly by the public, and concluded that 
“patients and health services are getting a poor return on this 
investment”.
Although drug development and evaluation are not 
the only components of project collaboration between 
academia and industry, they have yet to be addressed fully 
in ethical analyses of unbalanced collaboration. Garattini 
and Chalmers have also assessed the transparency of drug 
testing by the European Medicines Evaluation Agency 
and by the US Food and Drug Administration, and found 
both to be inadequate, with the European system being the 
least transparent. Their recommendations are for stronger 
involvement of patient interests in therapeutic research 
agendas, transparency in drug evaluation enshrined in law, 
independent drug evaluation, and demonstration of added 
value for all new drugs.4
A number of influential US authors from professional 
medical associations, including academia and journal 
  editors, have also investigated their financial relationships 
with pharmaceutical and medical device companies, and 
have requested stronger guidelines for controlling conflicts 
of interest, because the present policies “… are not uniform 
and often lack stringency”.5
A recent thought-provoking personal analysis by one 
clinical scientist strongly supports the conclusions of the 
professional medical associations, and puts the dilemmas and 
problems of conflicts of interests into the context of flesh and 
blood, recognizable to all clinical scientists and members of 
national ethical control systems.6
Particular ethical dilemmas appear in collaboration 
between industries from developed countries and scientists 
from both developing and developed countries. A publica-
tion by the Nuffield Council on Bioethics in 20027 dealt 
thoroughly with such problems, compared national guid-
ance in Denmark and Uganda, and also presenting a sur-
vey of international guidelines for transparency of   ethical 
dilemmas.
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Practical guidelines
In 2010, the Singapore Statement on Research Integrity, 
comprising four principles and 14 responsibilities, now 
enables readers to put this ethical subtopic into an overall 
perspective.8 Instead of providing a detailed description of 
contemporary project examples with ethical dilemmas, the 
present commentary concentrates on basic principles which 
can be practically applied when industries and academic 
researchers plan to work together on individual projects. 
These principles aim to balance the rights, interests, and 
duties of participating patients, volunteers, industry repre-
sentatives, and biomedical scientists in an equitable manner. 
The protocol must provide a thorough description of:
•	 Intended authorship order independent of any hierarchic 
titular order
•	 A fixed schedule and key agenda for project meetings
•	 Any chairperson shifts and obligatory detailed report-
ing of project meetings and agreements on project plan 
changes
•	 Any future members of the author group, balanced 
between disciplinary groups
•	 Equal distribution, blinding, and collation of all project 
data for all disciplinary groups
•	 A fixed plan for exchange of manuscripts at the 
proofing stage with the aim of agreement and common 
authorship
•	 A contractual description of procedures, if agreement on 
the final content of the manuscript cannot be reached, eg, 
a reflection period of three months, and after this, the right 
for both groups to publish their own version, with due 
consideration of any patenting issues; if a national inde-
pendent board for investigation of scientific dishonesty 
exists, and if suspicions of dishonesty have arisen, the 
possibility for one of the collaborators to involve such a 
board must exist
•	 Role of all members of the project group must be listed 
and signed by all authors before the final manuscript 
is submitted to the editor of the intended journal for 
publication.
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